LogicBio Therapeutics Inc

NASDAQ:LOGC   10:23:10 AM EDT
4.56
-0.15 (-3.18%)
Products, Strategic Combinations

LogicBio Therapeutics Announces Strategic Collaboration And Option Agreement With Canbridge Pharmaceuticals Leveraging Gene Editing And Gene Delivery Platforms

Published: 04/27/2021 12:14 GMT
LogicBio Therapeutics Inc (LOGC) - Logicbio Therapeutics Announces Strategic Collaboration and Option Agreement With Canbridge Pharmaceuticals Leveraging Gene Editing and Gene Delivery Platforms.
Logicbio Therapeutics Inc - Logicbio Grants Exclusive Option to License Lb-001 in Greater China.
Logicbio Therapeutics Inc - Deal Grants Worldwide License for Aav Sl65.
Logicbio Therapeutics - Agreement Includes Upfront Payment in Addition to Up to $581 Million in Options, Milestones Payments, Up to Double-digit Royalties.
Logicbio Therapeutics Inc - Logicbio is Eligible to Receive an Upfront Payment of $10 Million.